FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W77164094> ?p ?o ?g. }

• W77164094 abstract "Dipyridamole, an inhibitor of nucleoside transport, increases the activity of 5-fluorouracil in a dose-dependent manner. The purpose of the present study was to determine whether dipyridamole with 5-fluorouracil and leucovorin gave an improved therapeutic outcome. Sixty patients entered in the present pilot study had previously received 5-fluorouracil (450 mg/m2) and leucovorin (100 mg/m2), every week, and relapsed during this treatment, which ended at least 6 weeks prior to study entry. Dipyridamole was administered at three different dosing schedules (DS) and methods of administration in three groups of patients. DS I: dipyridamole, 30 mg/m2 in normal saline solution, in 90 min iv infusion, followed by leucovorin, 100 mg/m2 iv push, followed by 5-fluorouracil, 450 mg/m2 in normal saline solution, in 60 min iv infusion, dipyridamole tablets (75 mg) every 12 hrs, continuously during the time of chemotherapy. DS II: dipyridamole, 50 mg/m2 in normal saline solution, in 90 min iv infusion, and the rest was the same as DS I. DS III: without oral dipyridamole, patients received dipyridamole (50 mg/m2) iv in the same manner as in DS I and II. Treatment was continued until tumor progression or unacceptable toxicity. All patients (n = 60) entered in the present study were assessable for response and toxicity. No complete response was observed. No patient at DS I responded, whereas 2 patients at DS II and 3 at DS III had a partial response (P <0.1). Stable disease was found with DS I (n = 1), DS II (n = 8) and DS III (n = 9) (P <0.01). More patients progressed at DS I (n = 19) than at DS II (n = 10) and DS III (n = 8) (P <0.0007). The median duration of response was 11 weeks (range, 8-16). Time to progression was 17 weeks for DS I, 15 weeks (range, 10-19) for DS II, and 14 weeks (range, 11-21) for DS III (P = 0.43). Median survival did not differ significantly between DS I (29 weeks; range, 14-48), DS II(31.5 weeks; range, 17-63) and DS III (36 weeks; range, 16-58) (P = 0.2). Neutropenia was most severe with DS I (grade 2, P<0.01) and DS II (grade 1, P<0.05) and nausea/vomiting with DS I (grade 0, P < 0.0005, grade 1, P <0.0002, grade 2, P <0.02) and DS III (grade 3, P<0.0009). Diarrhea was most severe in DS II (grade 3, P <0.005). Mucositis was increased in DS II (grade 0, P <0.008), anorexia in DS II (grade 0, P <0.032) and fatigue in DS I (grade 0, P <0.003). More patients in DS I than with the other two DS experienced headache (P <0.044). According to the response achieved at DS III (15% partial response and 45% stable disease) and the toxicity which was well tolerated mainly in this DS (except for nausea and vomiting grade 3, P <0.009), it can be stated that DS III is the appropriate dose and the simplest schedule of administration (administration of dipyridamole during therapy only). In conclusion, it appears that dipyridamole might still have a role in enhancing the clinical activity of drugs involved in the inhibition of the thymidylate synthetase biochemical pathway and its activity in combination with these agents (5-fluorouracil + leucovorin) as frontline treatment should therefore be explored in future phase II studies." @default.
• W77164094 created "2016-06-24" @default.
• W77164094 creator A5001577925 @default.
• W77164094 creator A5013596267 @default.
• W77164094 creator A5016456674 @default.
• W77164094 creator A5029737032 @default.
• W77164094 creator A5035246805 @default.
• W77164094 creator A5039082324 @default.
• W77164094 creator A5071758598 @default.
• W77164094 creator A5072956257 @default.
• W77164094 creator A5077554624 @default.
• W77164094 creator A5086606757 @default.
• W77164094 creator A5089910357 @default.
• W77164094 date "2001-09-01" @default.
• W77164094 modified "2023-10-18" @default.
• W77164094 title "Leucovorin + 5-Fluorouracil plus Dipyridamole in Leucovorin + 5-Fluorouracil-Pretreated Patients with Advanced Colorectal Cancer: A Pilot Study of Three Different Dipyridamole Regimens" @default.
• W77164094 cites W166731374 @default.
• W77164094 cites W1875502685 @default.
• W77164094 cites W1975314903 @default.
• W77164094 cites W1977167317 @default.
• W77164094 cites W1997231925 @default.
• W77164094 cites W2006824814 @default.
• W77164094 cites W2013685483 @default.
• W77164094 cites W2019566621 @default.
• W77164094 cites W2032166380 @default.
• W77164094 cites W2084184339 @default.
• W77164094 cites W2096122707 @default.
• W77164094 cites W2128447158 @default.
• W77164094 cites W2161618993 @default.
• W77164094 cites W2163394854 @default.
• W77164094 cites W2167805334 @default.
• W77164094 cites W2173822384 @default.
• W77164094 cites W2314927739 @default.
• W77164094 cites W2331163355 @default.
• W77164094 cites W2397691982 @default.
• W77164094 cites W2443169085 @default.
• W77164094 cites W2462217852 @default.
• W77164094 cites W4238847870 @default.
• W77164094 cites W4293241248 @default.
• W77164094 doi "https://doi.org/10.1177/030089160108700505" @default.
• W77164094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11765178" @default.
• W77164094 hasPublicationYear "2001" @default.
• W77164094 type Work @default.
• W77164094 sameAs 77164094 @default.
• W77164094 citedByCount "2" @default.
• W77164094 countsByYear W771640942016 @default.
• W77164094 crossrefType "journal-article" @default.
• W77164094 hasAuthorship W77164094A5001577925 @default.
• W77164094 hasAuthorship W77164094A5013596267 @default.
• W77164094 hasAuthorship W77164094A5016456674 @default.
• W77164094 hasAuthorship W77164094A5029737032 @default.
• W77164094 hasAuthorship W77164094A5035246805 @default.
• W77164094 hasAuthorship W77164094A5039082324 @default.
• W77164094 hasAuthorship W77164094A5071758598 @default.
• W77164094 hasAuthorship W77164094A5072956257 @default.
• W77164094 hasAuthorship W77164094A5077554624 @default.
• W77164094 hasAuthorship W77164094A5086606757 @default.
• W77164094 hasAuthorship W77164094A5089910357 @default.
• W77164094 hasConcept C126322002 @default.
• W77164094 hasConcept C2776694085 @default.
• W77164094 hasConcept C2776890861 @default.
• W77164094 hasConcept C2777288759 @default.
• W77164094 hasConcept C2777397205 @default.
• W77164094 hasConcept C2780456651 @default.
• W77164094 hasConcept C29730261 @default.
• W77164094 hasConcept C71924100 @default.
• W77164094 hasConcept C90924648 @default.
• W77164094 hasConceptScore W77164094C126322002 @default.
• W77164094 hasConceptScore W77164094C2776694085 @default.
• W77164094 hasConceptScore W77164094C2776890861 @default.
• W77164094 hasConceptScore W77164094C2777288759 @default.
• W77164094 hasConceptScore W77164094C2777397205 @default.
• W77164094 hasConceptScore W77164094C2780456651 @default.
• W77164094 hasConceptScore W77164094C29730261 @default.
• W77164094 hasConceptScore W77164094C71924100 @default.
• W77164094 hasConceptScore W77164094C90924648 @default.
• W77164094 hasLocation W771640941 @default.
• W77164094 hasLocation W771640942 @default.
• W77164094 hasOpenAccess W77164094 @default.
• W77164094 hasPrimaryLocation W771640941 @default.
• W77164094 hasRelatedWork W2005283848 @default.
• W77164094 hasRelatedWork W2051036097 @default.
• W77164094 hasRelatedWork W206168401 @default.
• W77164094 hasRelatedWork W2094700497 @default.
• W77164094 hasRelatedWork W2289397400 @default.
• W77164094 hasRelatedWork W2437895651 @default.
• W77164094 hasRelatedWork W2460974733 @default.
• W77164094 hasRelatedWork W2586724005 @default.
• W77164094 hasRelatedWork W4239546014 @default.
• W77164094 hasRelatedWork W4246896749 @default.
• W77164094 isParatext "false" @default.
• W77164094 isRetracted "false" @default.
• W77164094 magId "77164094" @default.
• W77164094 workType "article" @default.